Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $1.1 billion.

  • Immunocore Holdings' Liabilities and Shareholders Equity rose 164.68% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 1415.01%. This contributed to the annual value of $1.0 billion for FY2024, which is 6909.62% up from last year.
  • Latest data reveals that Immunocore Holdings reported Liabilities and Shareholders Equity of $1.1 billion as of Q3 2025, which was up 164.68% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Liabilities and Shareholders Equity registered a high of $1.1 billion during Q3 2025, and its lowest value of $526.8 million during Q4 2022.
  • Its 4-year average for Liabilities and Shareholders Equity is $938.7 million, with a median of $1.0 billion in 2024.
  • Per our database at Business Quant, Immunocore Holdings' Liabilities and Shareholders Equity soared by 6909.62% in 2024 and then surged by 164.68% in 2025.
  • Quarter analysis of 4 years shows Immunocore Holdings' Liabilities and Shareholders Equity stood at $526.8 million in 2022, then grew by 13.33% to $597.0 million in 2023, then surged by 69.1% to $1.0 billion in 2024, then increased by 9.21% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.0 billion for Q1 2025.